Welcome
Support Centre
30 August 2014 
ISRCTN Register - International Standard Randomized Controlled Trial Number
Trial registration
Unique identification scheme
International databases
home  |   my details  |   ISRCTN Register  |   mRCT  |   links  |   information  |   news
Find trials
ISRCTN Register
tips on searching

Registration
New application
Updating record

Information
introduction
governing board
ISRCTN FAQs
data set
letter of agreement
request information
guidance notes
statistics

[ Print-friendly version ]
Does Adjuvant Zoledronic acid redUce REcurrence in patients with high risk localised breast cancer?
ISRCTN ISRCTN79831382
DOI 10.1186/ISRCTN79831382
ClinicalTrials.gov identifier NCT00072020
EudraCT number
Public title Does Adjuvant Zoledronic acid redUce REcurrence in patients with high risk localised breast cancer?
Scientific title
Acronym AZURE
Serial number at source N/A
Study hypothesis Adjuvant treatment with 4mg zoledronic acid plus chemotherapy and/or endocrine therapy is superior to chemotherapy and/or endocrine therapy alone in improving the disease-free and bone metastasis-free survival of women with breast cancer at high risk of relapse.
Lay summary Not provided at time of registration
Ethics approval West Midlands Research Ethics Committee (ref: 03/7/029)

Protocol Version 1.1, dated April 2003 - 19/05/2003;
Protocol Version 1.2, dated June 2003 - 31/07/2003;
Protocol Version 2, dated December 2003 - 08/01/2004;
Protocol Version 3, dated February 2004 - 24/02/2004;
Protocol Version 4, dated July 2005 - 23/07/2005;
Protocol Version 5, dated September 2007 - 08/10/2007;
Protocol Version 6, dated August 2008 - 24/09/2008;
Protocol Version 7, dated August 2010 - 26/08/2010

All other centres will seek ethics approval before recruitment of the first participant.
Study design Randomised controlled trial
Countries of recruitment Australia, Ireland, Portugal, Spain, Taiwan, Thailand, United Kingdom
Disease/condition/study domain Breast cancer
Participants - inclusion criteria Patients with stage II or III primary breast cancer

1. Female patients with Stage II/III primary breast cancer, with T stage ≥T1

2. Patients should be receiving/scheduled to receive chemotherapy and/or endocrine therapy

3. Patients receiving neo-adjuvant therapy
a. Must have tumour size of >5 cm (T3), features of locally advanced disease (T4) or biopsy-proven lymph node involvement

b. Should be scheduled to proceed to definitive surgery$ and/or radical radiotherapy with curative intent within 6 months of starting neoadjuvant therapy

c. Time between commencement of neoadjuvant treatment and planned start date of study drug should be ≤30 days

4. Patients receiving adjuvant therapy

a. Must have undergone complete primary tumour resection and treatment of the axillary lymph nodes*, without any prior neoadjuvant therapy#

b. Must have evidence of lymph node involvement

c. Time between definitive surgery and planned start date of study drug should be ≤60 days

5. Performance status: Karnofsky Index ≥80% or Eastern Cooperative Oncology Group (ECOG) 0 and 1

6. Women of childbearing potential must be using a reliable and appropriate method of contraception

7. Age ≥18 years

8. Patient must have given written informed consent prior to any study-specific procedures
$Final definitive surgery is considered to include re-operation for inadequate margins or another bona fide oncological indication
*Patients whose treatment plan is to proceed to further primary tumour resection and/or treatment of the axillary lymph nodes (e.g. clearance or radiotherapy) with curative intent after completion of chemotherapy would be eligible but this must be completed within 9 months of randomisation
#Pre-operative endocrine therapy of less than 30 days would not be classed as prior neoadjuvant therapy
Participants - exclusion criteria 1. Metastatic or recurrent breast cancer or a history of breast cancer (aside from ductal carcinoma in situ [DCIS] or lobular carcinoma in situ [LCIS]) prior to the currently diagnosed case
2. History of prior cancers within the preceding 5 years (including previous contralateral breast cancer), aside from non-melanomatous skin cancer or carcinoma in situ of the uterine cervix treated with curative intent
3. History of diseases with influence on bone metabolism, such as Pagetís disease of bone, primary hyperparathyroidism or osteoporosis requiring treatment at the time of study entry or considered likely to become necessary within the subsequent 6 months
4. Severe physical or psychological concomitant diseases that might impair compliance with the provisions of the study protocol
5. Prior treatment with bisphosphonates within the past year
6. Serum creatinine >1.5 x Upper Limit of Normal
7. Known hypersensitivity to bisphosphonates
8. Current active dental problems including dental abscess or infection of the jawbone (maxilla or mandible), or a current or prior diagnosis of osteonecrosis of the jaw (ONJ)
9. Recent (within 4 weeks of study entry) or planned dental or jaw surgery (e.g. extractions, implants). Recent dental fillings, teeth scaling and polishing or minor gingival surgery do not exclude the patient.
10. Pregnancy or breast-feeding
11. Use of other investigational drugs in the 30 days prior to study entry. (Patients may be receiving treatments within a clinical trial providing the treatment under test has a licensed indication within your country).
Anticipated start date 01/09/2003
Anticipated end date 30/09/2006
Status of trial Completed
Patient information material
Target number of participants Added 05/05/2011: target 3300 (3352 at time of registration), recruited 3360
Interventions Patients are randomised to receive either (neo)adjuvant chemotherapy and/or endocrine therapy alone, or (neo)adjuvant chemotherapy and/or hormonal therapy plus zoledronic acid.

The AZURE trial reached target recruitment and therefore closed to recruitment on 20th Jan 2006.
Primary outcome measure(s) To determine whether zoledronic acid with chemotherapy and/or endocrine therapy is superior to chemotherapy and/or endocrine therapy alone in improving disease-free survival
Secondary outcome measure(s) To determine whether zoledronic acid with chemotherapy and/or endocrine therapy is superior to chemotherapy and/or endocrine therapy alone in terms of:
1. Invasive disease-free survival (Added 05/05/2011)
2. Time to bone metastases as first recurrence
3. Time to bone metastases per se
4. Time to distant metastases
5. Overall survival
6. Reducing skeletal-related events* prior to development of bone metastases
7. Reducing skeletal-related events* following development of bone metastases
Additional secondary objectives are:
1. To assess the safety and toxicity of zoledronic acid in this clinical setting
2. To evaluate the influence of prognostic factors, such as estrogen receptor (ER)/progesterone receptor (PR) status, tumour, node, metastasis (TNM) stage, tumour grade, human epidermal growth factor receptor 2 (HER2/neu) (if available) and menopausal status on treatment outcome
3. To use proteomics, tissue micro-array and other modern techniques to identify more specific prognostic indicators for the development of bone metastases and factors that are able to predict specific benefit from bisphosphonate treatment (to be investigated via sub-studies)
* Defined as: fractures, spinal cord compression, radiation therapy to bone, surgery to bone and hypercalcaemia
Sources of funding Novartis Pharmaceuticals, USA
Trial website
Publications 1. 2011 safety and tolerability results in http://www.ncbi.nlm.nih.gov/pubmed/21394500
2. 2011 results in http://www.ncbi.nlm.nih.gov/pubmed/21995387
Contact name Mrs  Claire  Davies
  Address Senior Trial Manager
Clinical Trials Research Unit
University of Leeds
  City/town Leeds
  Zip/Postcode LS2 9JT
  Country United Kingdom
  Tel +44 (0)113 343 1498
  Fax +44 (0)113 343 1487
  Email c.l.davies@leeds.ac.uk
Sponsor The University of Sheffield (UK)
  Address Western Bank


UK
  City/town Sheffield
  Zip/Postcode S10 2TN
  Country United Kingdom
Date applied 20/08/2003
Last edited 08/11/2011
Date ISRCTN assigned 20/08/2003
Submit your trial protocol
Submit to Trials journal
Follow us on Twitter
© 2014 ISRCTN unless otherwise stated.